CTOs on the Move

The Mighty

www.themighty.com

 
The Mighty is a digital health community created to empower and connect people facing health challenges and disabilities. We have over 2.5 million registered users and are adding a new one every 20 seconds. Our stories and videos are viewed and shared more than 90 million times a month. But those are just stats. This experience from a community member is what we`re really after: “How is it that I read an essay on The Mighty and it is the only place in the world where I feel truly understood? Time and time again you speak to me through your ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.themighty.com
  • 210 N Glenoaks Boulevard Suite C
    Burbank, CA USA 91502
  • Phone: 213.379.2407

Executives

Name Title Contact Details
Peter Wang
Chief Technology Officer Profile

Similar Companies

VITAS Healthcare

VITAS Innovative Hospice Care, a pioneer and leader in the hospice movement since 1978, is the one of the nations largest providers of end-of-life care.

Community Healthcare Network of New York

Community Healthcare Network of New York is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Community Healthcare Network of New York is based in New York, NY. You can find more information on Community Healthcare Network of New York at www.chnnyc.org

Codman Square Health Center

The mission of Codman Square Health Center is to serve as a resource for improving the physical, mental and social well-being of the community. Codman Square Health Center is an award-winning, community-based, outpatient health care and multi-service center in the heart of Dorchester. We opened our doors in 1979 with a dream: to build the best urban community in America. With a holistic and partnership-oriented approach, we ensure access to quality health care and other supportive services through a highly successful integrated model.

Clinipace

At Clinipace, a global, full-service contract research organization (CRO), our approach to clinical research is personal. We deliver a level of collaboration and flexibility not possible in a traditional CRO environment. Our personalized services and solutions, local regulatory expertise and therapeutic leadership are designed to face the most difficult industry challenges across all major therapeutic areas including oncology, gastroenterology, nephrology and urology. We strive to improve the way clinical research is performed and impact the future of health care using the most advanced technology and a CHALLENGE ACCEPTED approach. In April 2021, Clinipace & dMed merged creating a differentiated mid-size CRO with the largest Asia-Pacific presence. We are proud to have such a strong group of global investors focused on improving healthcare outcomes and giving sponsors a better CRO choice. dMed`s 2019 acquisition of Target Health commenced the process of building a Next Generation global CRO for biotech and pharmaceutical companies. Our investors have invested over $230M to build the next great global CRO. dMed`s acquisition of Target Health in 2019 began dMed`s evolution from a local to global CRO. Target Health LLC is owned by dMedClinical Co. Ltd., a privately held company that is majority owned, operated, managed, and controlled by a U.S. citizen and foreign entities located in the People`s Republic of China. Dr. Lingshi Tan, is the aforementioned U.S. citizen currently residing in Shanghai, China. Dr. Tan moved to Shanghai (from New York) to become Pfizer`s VP of Worldwide Development Operations, and Chairman and General Manager of Pfizer (China) Research & Development Co. Dr. Tan founded dMed in 2016 to satisfy the local demand for a high quality, responsive, flexible CRO.

Catabasis

At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our SMART (Safely Metabolized And Rationally Targeted) Linker drug discovery platform enables us to engineer molecules that simultaneously modulate multiple targets in a disease. We are applying our SMART LinkerSM platform to build an internal pipeline of product candidates for rare diseases and plan to pursue partnerships to develop additional product candidates.